แบ่งปัน เบ่งบาน สร้างพลังใจสำหรับทุกคน
A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.
Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI IFM_05-May 2022
Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. A significant number of patients (roughly 27%) had
Lenalidomide was the primary drug used for maintenance in this study. Key Findings: IFM_05-May 2022
One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations